- Alternating, intravenous administration of two replicating arenaviral vectors induce tumor-specific responses exceeding 50% of the circulating CD8 T cells
- 2-vector method resulted in tumor cures and long-term immunity in opposition to tumor rechallenge
- Publication underscores the potential of HOOKIPA’s engineered arenavirus platform as a brand new class of most cancers immunotherapeutics, presently being evaluated in a Section 1/2 scientific trial in HPV16+ cancers
NEW YORK and VIENNA, Austria, March 04, 2021 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), an organization creating a brand new class of immunotherapeutics primarily based on its proprietary arenavirus platform, at the moment introduced the publication of pre-clinical information highlighting the potential of its alternating 2-vector, intravenously administered most cancers therapeutics within the peer-reviewed journal, Cell Stories Drugs. The publication, which is obtainable on-line now, will seem within the 16 March print subject.
“The pre-clinical information revealed in Cell Stories Drugs underscore the potential of our engineered arenavirus platform to redefine success in most cancers immunotherapy. Particularly, our alternating 2-vector method delivered a considerable tumor-specific response, leading to tumor cures and long-term anti-tumor immunity in a pre-clinical setting,” stated Joern Aldag, Chief Govt Officer at HOOKIPA. “The information on this peer-reviewed publication present the scientific substantiation for the continued scientific trial of the alternating 2-vector remedy for Human Papillomavirus 16-positive (HPV16+) cancers in addition to for advancing to prostate most cancers.”
Pre-clinical information featured within the article confirmed that intravenous, alternating administration of two totally different replicating arenaviral vectors that specific the identical antigen induces potent T cell response, exceeding 50% of the circulating T cell pool, and strong anti-tumor exercise. The anti-tumor exercise and really excessive T cell technology had been demonstrated each with onco-viral antigens and in addition with a most cancers self-antigen, illustrating the power of the arenaviral platform to interrupt tolerance.
Different key highlights from the paper embrace:
- Single-vector and alternating 2-vector remedy didn’t induce vector-neutralizing antibodies, supporting repeated intravenous administration
- Mice that cleared tumors after remedy had been shielded from tumor re-challenge
- Increasing on the information noticed with single-vector remedy, alternating 2-vector remedy induced a good increased T cell response and extra environment friendly tumor management
The examine on which this publication is predicated, was performed and led by a global group of researchers on the College of Basel.
HOOKIPA is evaluating its single-vector and alternating 2-vector applied sciences within the ongoing Section 1/2 scientific trial of its lead oncology candidates, HB-201 and HB-202. HB-201 and HB-202 use the LCMV and PICV arenaviral backbones, respectively, whereas expressing the identical antigen, an E7/E6 fusion protein derived from HPV16. Interim Phase 1 monotherapy data on HB-201 for the remedy of superior HPV16+ cancers confirmed promising anti-tumor exercise and favorable tolerability. Information demonstrated responses and secure illness in head and neck most cancers sufferers who failed prior normal of care remedy, platinum remedy, PD(L)1 inhibitor, or each. Preliminary information on HB-201 and HB-202 as a replicating 2-vector remedy are anticipated by mid-2021. HOOKIPA’s HB-300 program for prostate most cancers additionally makes use of the LCMV and PICV arenaviral backbones directed in opposition to three validated antigens for prostate most cancers: PAP, PSA, and PSMA.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical firm creating a brand new class of immunotherapeutics primarily based on its proprietary arenavirus platform that reprograms the physique’s immune system.
HOOKIPA’s proprietary arenavirus-based applied sciences, non-replicating and replicating, induce strong antigen-specific CD8+ T cells and pathogen-neutralizing antibodies. HOOKIPA’s viral vectors goal antigen presenting cells in vivo to activate the immune system. Each applied sciences allow repeat administration to enhance and refresh immune responses. Our replicating arenavirus expertise has the potential to induce CD8+ T cell response ranges beforehand not achieved by different immuno-therapy approaches.
HOOKIPA is constructing a proprietary immuno-oncology pipeline by focusing on virally mediated most cancers antigens, self-antigens and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in growth for the remedy of Human Papilloma Virus 16-positive cancers in a Section 1/2 scientific trial.
HOOKIPA’s non-replicating prophylactic Cytomegalovirus (CMV) vaccine candidate, HB-101, is presently in a Section 2 scientific trial for sufferers awaiting kidney transplantation. To broaden its infectious illness portfolio, HOOKIPA entered right into a collaboration and licensing settlement with Gilead Sciences, Inc. to analysis arenavirus-based useful cures for HIV and continual hepatitis B infections.
Discover out extra about HOOKIPA on-line at www.hookipapharma.com.
HOOKIPA Ahead Trying Statements
Sure statements set forth on this press launch represent “forward-looking” statements inside the which means of the Personal Securities Litigation Reform Act of 1995, as amended. Ahead-looking statements might be recognized by phrases reminiscent of “believes,” “expects,” “plans,” “potential,” “would” or comparable expressions and the adverse of these phrases. Such forward-looking statements contain substantial dangers and uncertainties that would trigger HOOKIPA’s analysis and scientific growth packages, future outcomes, efficiency or achievements to vary considerably from these expressed or implied by the forward-looking statements. Such dangers and uncertainties embrace, amongst others, the uncertainties inherent within the drug growth course of, together with HOOKIPA’s packages’ early stage of growth, the method of designing and conducting preclinical and scientific trials, the regulatory approval processes, the timing of regulatory filings, the challenges related to manufacturing drug merchandise, HOOKIPA’s potential to efficiently set up, shield and defend its mental property, dangers referring to enterprise interruptions ensuing from the coronavirus (COVID-19) illness outbreak or comparable public well being crises, the affect of COVID-19 on the enrollment of sufferers and timing of scientific outcomes for HB-101 and different packages, and different issues that would have an effect on the sufficiency of present money to fund operations and HOOKIPA’s potential to attain the milestones underneath the settlement with Gilead. HOOKIPA undertakes no obligation to replace or revise any forward-looking statements. For an additional description of the dangers and uncertainties that would trigger precise outcomes to vary from these expressed in these forward-looking statements, in addition to dangers referring to the enterprise of the corporate normally, see HOOKIPA’s quarterly report on Type 10-Q for the quarter ended September 30, 2020 which is obtainable on the Safety and Change Fee’s web site at www.sec.gov and HOOKIPA’s web site at www.hookipapharma.com.
Buyers and others ought to word that we announce materials monetary info to our traders utilizing our investor relations web site (https://ir.hookipapharma.com/), SEC filings, press releases, public convention calls and webcasts. We use these channels, in addition to social media, to speak with our members and the general public about our firm, our companies and different points. It’s attainable that the knowledge we publish on social media might be deemed to be materials info. Due to this fact, we encourage traders, the media, and others serious about our firm to assessment the knowledge we publish on the U.S. social media channels listed on our investor relations web site.